XTL Biopharmaceuticals Ltd. (TLV: XTLB)

Market Cap	122.41M
Revenue (ttm)	n/a
Net Income (ttm)	-1.40M
Shares Out	1.22B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,000
Open	10.10
Previous Close	10.10
Day's Range	10.00 - 10.10
52-Week Range	0.03 - 10.10
Beta	0.94
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: XTLB

Financial Performance

Financial numbers in USD